Avrobio price target lowered to $2.00 from $2.50 at Wells Fargo

Wells Fargo lowered the firm’s price target on Avrobio to $2.00 from $2.50 and keeps an Overweight rating on the shares. There is upside to current levels based on cash position alone with Avrobio exploring strategic alternatives, and Wells Fargo sees further upside from the company’s technology and manufacturing platforms, the analyst tells investors in a research note.